Trikafta is named as an intervention in 3 current clinical trials in our Canada and Italy registers. 3 are recruiting patients now. All registered phases are Observational. The sponsor with the most trials is University of British Columbia (2). The most-studied condition is Cystic Fibrosis.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Canadian Observational Study Evaluating the Long-term IMPACT of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators on People With CF
NCT05200429 · ClinicalTrials.gov ↗ · Cystic Fibrosis
|
Observational | Recruiting | University of British Columbia | Canada |
|
Trikafta Exercise Study in Cystic Fibrosis
NCT05279040 · ClinicalTrials.gov ↗ · Cystic Fibrosis, Lung Diseases
|
Observational | Recruiting | University of British Columbia | Canada |
|
Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.
NCT07363304 · ClinicalTrials.gov ↗ · Cystic Fibrosis (CF)
|
Observational | Recruiting | Meyer Children's Hospital IRCCS | Italy |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| University of British Columbia | 2 |
| Meyer Children's Hospital IRCCS | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 2 | 2 |
| Clinical trials in Italy | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our Canada and Italy registers name Trikafta as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 3 trials are recruiting: 2 with sites in Canada and 1 with sites in Italy. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
University of British Columbia (2) and Meyer Children's Hospital IRCCS (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Trikafta works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Trikafta works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Trikafta (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.